BioWorld

March 3, 2003

Stock Winners and Losers For The Week

Deal-Making Rules Changing; Pharma, Biotechs Shop Around

Science is all about experiments, so here's an idea for the blackboard: Imagine a world where biotechnology pays pharmaceutical companies to develop compounds. Read More

Biotech Mergers And Acquisitions: Oct. 17, 2002 - Feb. 26, 2003#

BioWorld Stock Report For Public Biotechnology Companies

Money Raised Year To Date

Today's news in brief

BioWorld

BioWorld briefs for Dec. 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 12, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...

DEE-lightful: Praxis’ phase II results allow stock to flex its muscle

BioWorld

Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...